Actinium Pharmaceuticals ATNM
NYSE ATNM
$1.59 +0.02 (+1.28%)
As of: Nov 11, 2026 · 3:59 PM EST

Actinium Pharmaceuticals (ATNM) Current Deferred Revenue (2021 - 2025)

Updated

Actinium Pharmaceuticals' Current Deferred Revenue was $100,000 in Q2 2023, down 50.0% from $200,000 a year earlier.

Analysis

Actinium Pharmaceuticals (ATNM) Current Deferred Revenue (2021 - 2025) Analysis & Trends

At the end of FY2021, Current Deferred Revenue at Actinium Pharmaceuticals came in at $1 million.

  • Quarterly Current Deferred Revenue has moved between $100,000 (Q1 2022) and $1 million (Q4 2021) over five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Actinium Pharmaceuticals 49.05 Mn -130.95 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 8.55 Mn
Dec 31, 2024 8.22 Mn
Jun 30, 2023 100,000.00
Dec 31, 2022 100,000.00
Sep 30, 2022 100,000.00
Jun 30, 2022 200,000.00
Mar 31, 2022 100,000.00
Dec 31, 2021 1.00 Mn
Sep 30, 2021 200,000.00
API Access

Actinium Pharmaceuticals Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=ATNM&period=max&api_key=YOUR_API_KEY